Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Orion Corporation Orion Pharma
Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 4 ans
SAFETY AND TOLERABILITY OF ODM-201 IN PATIENTS WITH PROSTATE CANCER: EXTENSION STUDY TO STUDY 3104001
The primary objective of this extension study is to gain more information about the long-term safety and tolerability of ODM-201.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
Update Il y a 4 ans
Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-treated Parkinson's disease patients
to provide efficacy data of the direct switch from levodopa/carbidopa or levodopa/benserazide to levodopa/carbidopa/entacapone (Stalevo®) by clinical global impression of change (CGI-C) as judged by t...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 4 ans
Effects of single doses of Stalevo 200 and levodopa/carbidopa 200/50 mg on striatal 11C-raclopride binding potential in Parkinson’s disease patients with wearing-off symptoms. An open, randomised, active-controlled, two-period crossover study
To compare the effect of Stalevo 200 and Sinemet on the change of striatal (butaminal and caudate) 11C-raclopride binding potential (BP) from baseline in PD patients with wearing-off symptoms.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 4 ans
First in human study with ODM-207 in patients with selected advanced cancers to assess its safety and how the body affects it
Part 1: To evaluate the safety and tolerability, define the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) if possible, and define the recommended doses and dosing schedules of ODM...
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Orion Corporation Orion Pharma
Update Il y a 4 ans
A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF ODM-201 IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Studio multinazionale, randomizzato, in doppio cieco, controllato con placebo, di Fase III, per valutare l’efficacia e la sicurezza di ODM-201 in pazienti di sesso maschile con cancro della prostata resistente alla castrazione non metastatico ad alto rischio
The primary objective of this study is to demonstrate the superiority of ODM-201 vs. placebo in metastasis free survival (MFS) in patients with high-risk nmCRPC
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2